The analysis of the Phase 2/3 GAIN trial data revealed that participants with mild-to-moderate Alzheimer's disease who harbored the P. gingivalis pathogen experienced measurable improvements in neuropsychiatric symptoms, including disinhibition, elation, and apathy. Crucially, these clinical gains correlated with a reduction in the emotional burden carried by caregivers. In contrast, researchers observed no such benefits among Pg-negative patients, reinforcing the targeted nature of the therapy.

Michael Detke, Chief Medical Officer at Lighthouse Pharmaceuticals, noted that behavioral symptoms represent a primary challenge in Alzheimer’s care, yet currently lack disease-modifying treatments. The company is now pivoting toward LHP588, a next-generation inhibitor designed for once-daily dosing. The ongoing Phase 2 SPRING trial, which includes approximately 300 Pg-positive participants, is currently evaluating this candidate's efficacy in addressing both cognitive decline and behavioral disturbances.